Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress

Pubblicata il: 12/09/2016
Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress
Fonte: WWW.ILTEMPO.IT

Altri articoli che parlano di... Categorie (1) ADN Kronos - Merck, a leading science and technology company, today announced key symposia and more than 30 presentations of clinical data on Cladribine Tablets, an investigational, oral, small molecule for the treatment of relapsing-remitting multiple sclerosis (RRMS), and Rebif® (interferon beta-1a), the company's high-dose, high-frequency...

Continua a leggere
Notizie correlate
Commenta
FACEBOOK